{"id":"NCT01087502","sponsor":"Boehringer Ingelheim","briefTitle":"Safety and Efficacy of Linagliptin in Type-2-diabetes Mellitus Patients With Moderate to Severe Renal Impairment","officialTitle":"A Phase III, Randomised, Double-blind, Placebo-controlled Parallel Group Safety and Efficacy Study of Linagliptin (5 mg Administered Orally Once Daily) Over 12 Weeks Followed by a 40 Week Double-blind Extension Period (Placebo Patients Switched to Glimepiride) in Drug Naive or Previously Treated Type 2 Diabetic Patients With Moderate to Severe Renal Impairment and Insufficient Glycaemic Control","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-03","primaryCompletion":"2012-05","completion":null,"firstPosted":"2010-03-16","resultsPosted":"2013-10-17","lastUpdate":"2014-06-27"},"enrollment":241,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetes Mellitus, Type 2"],"interventions":[{"type":"DRUG","name":"Glimepiride","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Linagliptin","otherNames":[]}],"arms":[{"label":"Linagliptin","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Glimepiride","type":"ACTIVE_COMPARATOR"}],"summary":"The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to placebo given over 12 weeks in drug naive or previously treated type 2 diabetic patients with moderate to severe renal impairment and insufficient glycaemic control. In addition safety in this patient population with longer term (40 week) treatment in comparison to sulfonylurea drug (glimepiride).","primaryOutcome":{"measure":"HbA1c Change From Baseline to Week 12","timeFrame":"Baseline and week 12","effectByArm":[{"arm":"Placebo","deltaMin":-0.11,"sd":0.11},{"arm":"Linagliptin 5 mg","deltaMin":-0.53,"sd":0.11}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":52,"countries":["United States","Australia","Canada","Finland","Israel","Japan","New Zealand","Slovakia","Sweden"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":36,"n":122},"commonTop":["Hypoglycaemia","Hyperglycaemia","Nasopharyngitis","Upper respiratory tract infection","Back pain"]}}